[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Holland Bloorview Kids Rehabilitation Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":268},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,77,100,136,176,200,220,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622448","virtual-hand-arm-assessments-for-children-with-cerebral-palsy-100622448",false,"NCT07383753","Virtual Hand-Arm Assessments for Children With Cerebral Palsy","Virtual Hand-Arm Assessments for Children With Cerebral Palsy: Helping Us to Achieve Equity in Rehabilitation Care and Research","Inclusion Criteria:\n\n* Have a diagnosis of Cerebral Palsy\n* Are between 6 to 17 years old with sufficient cognitive capacity and cooperation to sit without a break for 30 minutes at a time\n* MACS levels I (handles objects easily) to III (handles objects with difficulty)\n* No visual limitations that would interfere with video conferencing\n* Has a caregiver willing to participate and can questions about preferences\n* Have an appropriate device and internet access for video conferencing\n\nExclusion Criteria:\n\n\\- Active treatments (e.g. Botulinum Toxin injections or constraint therapy in the last two months, or upper extremity surgery in the last 6 months) that might impact upper limb function stability over the study period.","ALL","6 Years","17 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Cerebral palsy (CP) affects approximately 1 in 500 Canadian children, and the majority experience hand and arm limitations that impact independence, participation in daily activities, and overall quality of life. Many children require ongoing clinical assessments and therapy delivered in specialized centres, creating significant burden related to travel, scheduling, and interruptions to school and work. Barriers such as geography, socioeconomic factors, and pandemic-related service disruptions have further limited equitable access to in-person care. Although virtual care has expanded rapidly and families have expressed strong interest in hybrid care models, there is currently no validated approach for conducting comprehensive virtual hand-arm assessments for children with CP. Virtual administration of standardized assessments, individualized goal-based evaluations, and naturalistic observation tools has not been systematically studied. Evidence is urgently needed to determine which assessments can be administered virtually, how acceptable and feasible they are for families, and whether virtual and in-person assessment methods produce equivalent results.",[25],"Cerebral Palsy (CP)",[27,28,29,30,31],"Virtual assessment","Tele-rehabilitation","Remote upper limb assessment","Virtual care","Pediatric rehabilitation","RECRUITING","2026-02-12",{"date":35,"type":36},"2026-02-17","ACTUAL",{"date":38,"type":36},"2025-10-22",{"date":40,"type":21},"2027-01",{"name":42,"class":43},"Holland Bloorview Kids Rehabilitation Hospital","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100620634","validity-assessment-of-sensors-for-movement-tracking-with-childrenyouth-with-diverse-neuromotor-abilities-100620634","NCT07360171","Validity Assessment of Sensors for Movement Tracking With Children\u002FYouth With Diverse Neuromotor Abilities","MOCAP","Inclusion Criteria:\n\n1. Aged 5 to 24 years\n2. Sufficient motor skills to successfully play the game (i.e., able to lift hand above shoulder)\n3. Able to see and interact with the monitor - minimal visual or auditory impairments\n4. Willing to wear reflective stickers on skin and on tight fitting clothing\n5. Willing to wear athletic tape around arms and\u002For legs to secure loose clothing\n6. Mobility similar to GMFCS Levels I-III.\n\nExclusion Criteria:\n\n* Any injury\u002Fdisability that would make moderate exercise unsafe.\n* History of epilepsy aggravated by screen time. For the latter, the child will be eligible to participate if they safely participated in 1 hour of TV\u002Fvideo games per week as reported by the parent.",true,"5 Years","24 Years",{"count":20,"type":21},"The overall goal of this study is to establish the clinical utility and accuracy of markerless motion captures systems for tracking therapy exercises and movement during game play. Specific aims are:\n\n1. To evaluate the accuracy of the kinematic metrics tracked by marker-less motion capture systems by comparing them to the gold standard marker-based Motion Analysis system.\n2. To assess agreement between exercise repetition counts and clinical assessment scores determined from data collected by the markerless motion capture systems compared to the gold standard marker-based Motion Analysis system and a trained clinician.\n3. To explore the extent to which kinematic metrics collected during gameplay (e.g. smoothness of movement, symmetry index) can discriminate different motor abilities.\n4. To understand children's perspectives on motion capture video games in the context of rehabilitation.\n\nParticipants will:\n\nPerform active range of motion of each joint (3 repetitions, outside of the game environment) and rehabilitative movements within games developed at Holland Bloorview that target anatomical movements (e.g. shoulder abduction\u002Fadduction, shoulder flexion\u002Fextension, elbow flexion\u002Fextension, lateral trunk lean, hip flexion\u002Fextension, knee flexion\u002Fextension, trunk flexion\u002Fextension)\n\nPlay each mini game until 10 repetitions are made regarding the game objective or 2-minutes of game play is reached.",[58,25],"Cerebral Palsy",[60,61,62,63,64,65,66],"Home-Based Rehabilitation","Interactive Video Game Therapy","Gamified Rehabilitation","Digital Therapeutics","Tele-Rehabilitation","Active Video Gaming","Motion Analysis","NOT_YET_RECRUITING","2026-01-28",{"date":70,"type":36},"2026-01-30",{"date":72,"type":21},"2026-02-01",{"date":74,"type":21},"2027-12-31",{"name":42,"class":43},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":44},"100615188","bootle-blast-pilot-randomized-controlled-trial-100615188","NCT07289360","Bootle Blast: Pilot Randomized Controlled Trial","Testing a Mixed-Reality Video Game for Home-Based Practice of Arm-Hand Skills for Children With Cerebral Palsy: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of hemiplegic Cerebral Palsy\n* MACS levels I (handles objects easily) to III (handles objects with difficulty)\n* Aged 6 to 17 years with sufficient cognitive capacity and cooperation to play Bootle Blast and complete outcome assessments\n* Ability to communicate in English\n* Able to travel to Holland Bloorview, Grandview or CHEO and complete a total of 3 in-person study appointments\n* Has a large screen (e.g. TV) with an appropriate play space (3m x 3m) in front\n* At least intermittent access to the internet\n* Have time to play Bootle Blast for 15-20 minutes\u002Fday, 3-4 days\u002Fweek for 12 weeks.\n\nExclusion Criteria:\n\n* Received upper limb surgery, botulin toxin injections in the past 4 months, or constraint therapy\u002Fcasting in the previous 3 months that may be associated with changing abilities\n* Currently or anticipates receiving active treatments impacting upper limb function during the study period\n* Uncontrolled epilepsy that may be triggered by video game play\n* Medical condition impeding safe participation in physical activity associated with Bootle Blast\n* Visual limitations that interfere with Bootle Blast play",{"count":85,"type":21},46,"INTERVENTIONAL",[88],"NA","One in 500 Canadians has cerebral palsy (CP), a lifelong condition affecting movement and function. Physical and occupational therapies greatly benefit children with CP but can be costly and difficult to access. Children, parents, and clinicians are interested in using movement-tracking video games for home-based hand\u002Farm therapy. Yet, the technologies and evidence to support this approach are limited. We partnered with key stakeholders and an interdisciplinary team to co-create Bootle Blast. Bootle Blast tracks skeletal movements and interactions with real-life objects, engaging children in individualized play experiences rich in feedback, task specificity, and opportunities for goal-directed motor practice linked to meaningful activities.\n\nTo establish Bootle Blast's clinical effectiveness, a large-scale randomized controlled trial (RCT) is needed. Pilot RCTs provide important insights that position large-scale RCTs for success. As a result, the goal of this Pilot RCT is to test whether a mixed-reality video game intervention (i.e. Bootle Blast) can improve upper-limb function, activity, and participation in children and youth aged 6-17 years with hemiplegic cerebral palsy. The main questions it aims to answer are: (1) Is it feasible and acceptable for families to use Bootle Blast at home for 12 weeks? (2) Does the intervention show preliminary improvements in hand-arm motor outcomes compared to usual care?\n\nResearchers will compare an immediate Bootle Blast intervention group to a waitlist comparison group that continues usual care for 12 weeks to see whether access to Bootle Blast leads to increased practice, greater engagement, and improved motor outcomes.\n\nParticipants will:\n\nComplete three in-person assessments (baseline, 12 weeks, 24 weeks) with standardized motor and participation measures.\n\nBe randomized to begin 12 weeks of home-based Bootle Blast immediately or after a 12-week waitlist period.\n\nUse the Bootle Blast game at home for 15-20 minutes per day, 3-4 days per week, with all gameplay tracked automatically.\n\nA subset of participants will also receive weekly 10-minute support calls from a monitoring coach.",[25,91],"Hemiplegic Cerebral Palsy",[60,61,63,64,62],"2026-01-06",{"date":95,"type":36},"2026-01-08",{"date":97,"type":36},"2025-12-06",{"date":40,"type":21},{"name":42,"class":43},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":86,"phases":110,"briefSummary":111,"conditions":112,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100579773","comparing-digitally-and-traditionally-made-ankle-foot-orthoses-100579773","NCT06828653","Comparing Digitally and Traditionally Made Ankle Foot Orthoses","Feasibility RCT Evaluating Digitally and Traditionally Produced Ankle Foot Orthoses for Individuals With Impaired Lower Limb Function","Inclusion Criteria:\n\n* Participants must be aged 8 years or older.\n* Participants should have either flaccid or spastic paresis resulting from conditions such as cerebral palsy, stroke, spinal cord injury, spina bifida, or traumatic peripheral nerve injury, leading to lower limb mobility impairments.\n* Participants must require a custom articulating, rigid, or energy storage and return (ESR) AFO to improve physical function for one or both sides (unilateral or bilateral).\n* Participants must be able to ambulate independently, though the use of gait aids is permitted.\n* Participants must be capable of completing questionnaires with no more than orienting guidance.\n* Participants must meet the requirements to have their AFO funded by the Assistive Devices Program (ADP).\n\nExclusion Criteria:\n\n* Clients for whom the primary goal of the AFO includes wound management.\n* Those whose AFO is not worn for ambulation.\n* Clients with insensate feet or a history of ulcerations.\n* First-time AFO users.","8 Years",{"count":109,"type":21},50,[88],"The research is being done to compare two methods of creating AFOs: 1. The traditional method, which involves manually creating a mold from a plaster cast of the client's limb. This is time-consuming and labor-intensive; and 2. The newer method uses digital technology, such as 3D scanning and printing, to design and produce the AFOs, potentially making the process faster and less costly. We want to know whether AFOs made using digital technology can provide the same clinical benefits as those made traditionally.",[113,114,58,115,116,117,118],"Flaccid Paresis","Spastic Paresis","Stroke","Spinal Cord Injury","Spina Bifida","Traumatic Peripheral Nerve Injury",[120,121,122,123,124,125,126],"Ankle foot orthosis","ankle foot orthoses","digital ankle foot orthoses","digital technology","3D scanning","3D printing","randomized control trial","2025-11-18",{"date":129,"type":36},"2025-11-20",{"date":131,"type":36},"2025-09-05",{"date":133,"type":21},"2027-03-31",{"name":42,"class":43},2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":18,"enrollmentInfo":144,"targetDuration":4,"studyType":86,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. Have at least phrase speech, to allow for some self-report. So that results can be generalized to children and youth with NDD and various levels of ability, no IQ cut-off will be employed. Full-scale IQ (as measured by the Stanford-Binet) is measured to explore its effect on efficacy and safety\\*\n7. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n8. Ability to complete assessments in English\u002FFrench\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study",{"count":145,"type":21},130,[147],"PHASE2","There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166],"Neurodevelopmental Disorders","Autism","Autism Spectrum Disorder","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","ADHD","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD - Combined Type","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders","2025-07-14",{"date":169,"type":36},"2025-07-16",{"date":171,"type":36},"2024-09-16",{"date":173,"type":21},"2026-09",{"name":42,"class":43},8,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":182,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":86,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":76},"100365703","phase-2-a-pilot-study-of-an-antioxidant-cocktail-vs-placebo-in-the-treatment-of-children-and-adolescents-with-rett-syndrome-100365703","NCT04041713","A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome","Inclusion Criteria:\n\n1. Female outpatients 2-21 years of age inclusive.\n2. Diagnosis of Rett syndrome.\n3. At least partially ambulatory (may need assistive device to take a step).\n4. If already receiving stable interventions must meet the following criteria:\n\n   * If already receiving stable concomitant medications or nutraceuticals affecting behaviour, must be on a stable dose during the preceding 1 month prior to Screening (with the exception of fluoxetine, where a period of 6 weeks is needed), and will not electively initiate new or modify ongoing medications for study duration.\n5. Have normal laboratory test results at Screening\u002FBaseline. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.\n6. Ability to complete assessments, fluency in English (parent\u002Flegal guardian; participant, if verbal).\n7. Ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)\u002Flegal guardian(s).\n\nExclusion Criteria:\n\n1. Pregnant females; sexually active females on inadequate birth control (extremely unlikely in this population).\n2. Have another serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Have evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common pediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.).\n3. Have hypersensitivity to any components of Rett-T.\n4. Have one or more of the following: HIV, HBV, HCV, hemophilia (bleeding problems, recent nose and brain injuries), drug abuse, immunity disorder, major depressive episode or psychosis.\n5. Unable to tolerate venipuncture procedures for blood sampling.\n6. Receiving concomitant medications\u002Fnutraceuticals that include any of the components of Rett-T.\n7. Actively enrolled in another intervention study.","FEMALE","2 Years","21 Years",{"count":186,"type":21},35,[147],"This study will examine the potential efficacy and safety of Rett-T for core motor deficits of Rett syndrome, and will explore biological markers of safety and treatment response.",[190],"Rett Syndrome",[190,192,193],"Rett","RTT",{"date":169,"type":36},{"date":196,"type":21},"2025-10-01",{"date":198,"type":21},"2026-11-30",{"name":42,"class":43},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":76},"100493036","accuracy-of-community-general-pediatrician-diagnosis-of-autism-compared-to-a-multidisciplinary-team-assessment-100493036","NCT05699928","Accuracy of Community General Pediatrician Diagnosis of Autism Compared to a Multidisciplinary Team Assessment","Child Inclusion Criteria:\n\n* Must be referred to a general pediatrician participating in the study with any of the following issues: 1) Failed 18-month developmental screen (other than isolated motor delay); 2) Speech\u002Flanguage delay; 3) Social\u002Femotional delay\u002Fconcern; 4) Behavioral concerns, inattention, hyperactivity, or impulsivity; 5) Global developmental delay\u002Fconcern; 6) A referral with a query of ASD.\n* Age \\\u003C5 years 6 months\n* Resident of Ontario, Canada (support for travel is available for participants who live \\>100 km from Toronto)\n\nExclusion Criteria:\n\n* Child has already received a diagnosis of ASD\n\nFor the AAPLES exploratory objective:\n\nInclusion Criteria:\n\n* Child has a developmental age of 36 months or more (determined on Mullen Scales of Early Learning)\n* Child has flexible phrase speech\n\nExclusion Criteria:\n\n\\- Child has previously completed a virtual ASD diagnostic assessment","0 Months","64 Months",{"count":209,"type":21},200,"The goals of this diagnostic study are to determine how accurate general pediatricians are in autism spectrum disorder (ASD) diagnostic assessment and which children might be best suited for this type of assessment. The investigators will also evaluate the use of a new virtual diagnostic tool, the Autism Assessment for Preschoolers with Language Element Sequence (AAPLES).\n\nThe investigators will recruit twenty general pediatricians from across Ontario, Canada, as well as 200 of their patients (maximum 10 per pediatrician) who have been referred with possible ASD. The general pediatrician will complete their assessment and decide on a diagnosis, but will not tell the family. The ASD expert team, consisting of a developmental paediatrician and a psychologist, will also perform a diagnostic assessment without knowing the general pediatrician's opinion. The team will inform the family of their diagnostic opinion. Investigators will determine the diagnostic agreement between the two assessments. They will then determine which of the child's characteristics (age, sex, racial\u002Fethnic background, ASD features, developmental delays, having a sibling with ASD) predict agreement in diagnosis.\n\nSome children in the study will have the option of undergoing an additional virtual autism diagnostic assessment using the AAPLES. The clinician administering the AAPLES will not know the results of the other assessments. The investigators will measure diagnostic agreement between the clinician administering the AAPLES and the expert team.",[152],"2025-02-05",{"date":214,"type":36},"2025-02-07",{"date":216,"type":36},"2022-11-24",{"date":218,"type":21},"2025-03-31",{"name":42,"class":43},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":86,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":76},"100526001","phase-2-home-based-transcranial-direct-current-stimulation-tdcs-to-promote-social-communication-and-behaviour-in-children-with-autism-spectrum-disorder-asd-100526001","NCT06129058","Home-based Transcranial Direct Current Stimulation (tDCS) to Promote Social Communication and Behaviour in Children With Autism Spectrum Disorder (ASD)","Inclusion Criteria:\n\n* Children with a diagnosis of autism spectrum disorder and self-regulation impairment or social communication challenges\n* Able to participate in tDCS\n\nExclusion Criteria:\n\n* Children with contraindications to tDCS (history of seizures, family history of seizures, metal implants)\n* Co-existing neurological conditions (epilepsy, stroke, etc.)","9 Years","18 Years",{"count":229,"type":21},20,[147],"Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that can be delivered in a home setting. It is a safe and tolerable intervention that has shown promise for improving positive social communication and self-regulation in youth with Autism Spectrum Disorder (ASD). Children and youth with ASD will be randomized to At-home tDCS or sham control stimulation for 3 weeks. We will measure the effect of At-home tDCS on the brain mechanisms and clinical measures of social communication and self-regulation..",[152],[234,235,236],"tDCS","MRI","brain stimulation","2024-07-29",{"date":239,"type":36},"2024-07-30",{"date":241,"type":36},"2023-10-20",{"date":243,"type":21},"2025-09-30",{"name":42,"class":43},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":227,"enrollmentInfo":252,"targetDuration":4,"studyType":86,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":76},"100457386","phase-2-treatment-to-promote-self-regulation-in-children-with-autism-spectrum-disorder-100457386","NCT05235919","Treatment to Promote Self-regulation in Children With Autism Spectrum Disorder","Repetitive Transcranial Magnetic Stimulation to Promote Helpful Self-regulatory Behaviour in Children and Youth With Autism Spectrum Disorder","Inclusion Criteria:\n\n* Children with a diagnosis of autism spectrum disorder and self-regulation impairment or challenges\n* Able to participate in rTMS\n\nExclusion Criteria:\n\n* Children with autism spectrum disorder but no co-morbid self-regulation disorders.\n* Children with contraindications to TMS (history of seizures, family history of seizures, metal implants)\n* Co-existing neurological conditions (epilepsy, stroke, etc.)",{"count":109,"type":21},[147],"This study will evaluate the feasibility of repetitive Transcranial Magnetic Stimulation (rTMS) in Autism Spectrum Disorder (ASD) with self-regulation impairment. Baseline and follow-up participant visits will include behavioral assessments of self-regulation and magnetic resonance imaging (MRI) to determine neurophysiological outcomes before and after rTMS treatment.",[152,256],"Self-Regulation, Emotion",[258,259,235],"transcranial magnetic stimulation","rTMS","2024-07-25",{"date":262,"type":36},"2024-07-26",{"date":264,"type":36},"2022-09-22",{"date":266,"type":21},"2025-02",{"name":42,"class":43},""]